OHSU

IRB #

IRB00007669

Title

An Open Label, Multi-center, IRESSA Clinical Access Program of Gefitinib 250 mg (IRESSA) for the Continued Treatment of Patients in the United States Who Are Currently Benefiting or Have Benefited from Gefitinib Treatment

Principal Investigator

Jeremy Cetnar

Study Purpose

This Clinical Access Program has been set up to make sure patients in the United States who have been receiving and benefiting from the study drug Gefitinib (IRESSA) will have the option of continuing to receive it after September 30, 2011. Through this study, you can continue to receive the study drug as long as your doctor continues to order it for you.

Medical Condition(s)

Cancer

Eligibility Criteria

1. Male or female aged 18 years and over.
2. Patients who are currently receiving and benefiting or have previously benefited
from treatment with gefitinib through the IRESSAâ„¢ Access Program or patients
enrolled in an IND clinical trial that was IRB approved before 17 June 2005 and
who are currently benefiting or have benefited from treatment with gefitinib.

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

You will continue to receive the study drug until you and the investigator determine that you should stop taking it.

Minors Included

No

Contact

Knight Clinical Trials Information Line
503-494-1080

Sponsor

AstraZeneca, AB

Recruitment End

05/24/2018

Compensation Provided

No


Go Back